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The introduction of reduced-intensity conditioning (RIC) regimens made it possible to offer allogeneic he-
matopoietic cell transplantation (alloHCT) to older patients with myelodysplastic syndromes (MDS). How-
ever, the relative risks and beneﬁts of alloHCT compared with novel nontransplant therapies continue to be
the source of considerable uncertainty. We will perform a prospective biologic assignment trial to compare
RIC alloHCT with nontransplant therapies based on donor availability. Primary outcome is 3-year overall
survival. Secondary outcomes include leukemia-free survival, quality of life, and cost-effectiveness. Four
hundred patients will be enrolled over roughly 3 years. Planned subgroup analyses will evaluate key biologic
questions, such as the impact of age and response to hypomethylating agents on treatment effects. Findings
from this study potentially may set a new standard of care for older MDS patients who are considered
candidates for alloHCT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Myelodysplastic syndromes (MDS) represent a hetero-
geneous group of acquired malignant bone marrow disor-
ders characterized by high rates of apoptosis leading to
ineffective hematopoiesis [1]. An acquired bone marrow
failure picture ensues and leads to varying degrees of pe-
ripheral blood cytopenias and potentially fatal complica-
tions, including infection and bleeding [1,2]. MDS is mostedgments on page 1571.
quests: Wael Saber, MD, MS, Center for
ransplant Research, Medical College of
nue, Suite C5500, Milwaukee, WI 53226.
du (W. Saber).
2014 American Society for Blood and Marrow
14.06.010often diagnosed in elderly individuals with a median age of
76 years at diagnosis [3,4]. Overall, about 30% of individuals
with MDS progress to acute myeloid leukemia (AML),
although the probability of progression is largely determined
by disease risk at presentation [4,5] (eg, the 2-year risk of
progression to AML is 80% for those with high-risk disease
but only 10% among those with low-risk disease [6]).
The most widely used prognostic classiﬁcation system for
MDS is the International Prognostic Scoring System (IPSS),
which takes into account the number of bone marrow blasts,
cytogenetic abnormalities, and cytopenias [5]. The IPSS clas-
siﬁes patients into low-risk, intermediate-1, intermediate-2,
and high-risk stages. The median survival ranges from
5.7 years for those with low-risk disease to only months forTransplantation.
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(IPSS-R) [7], but to datemost clinical experience and conduct of
investigative clinical trials for MDS have used the original IPSS.
A wide range of therapeutic approaches exists for patients
with MDS, which are typically selected based on the patient’s
estimated risk of death [5-9]. Also, treatment guidelines have
been developed by independent groups [10,11]. Introduction
of hypomethylating agents (HMAs) prolongs progression-free
survival [12] and overall survival (OS) [13,14] and delays
transformation to AML [12-14]. However, to date, allogeneic
hematopoietic cell transplantation (alloHCT) remains the only
curative therapeutic modality available. Despite its curative
potential, because of the risk of nonrelapse mortality with
alloHCT in a population of mostly older individuals, many
patients with MDS are still not referred for transplant evalu-
ation [15]. A query of transplantation activity reported to the
Center for International Blood and Marrow Transplant
Research (CIBMTR) showed that of 3101 alloHCTs performed
in the United States between 2000 and 2010 forMDS, only 232
(7.5%) were among persons aged 65 years and older (unpub-
lished data; W.S., personal communication, June, 2012).
Studies have shown, however, that among patients who were
considered to be candidates for alloHCT and were referred to
the transplant programs, age was not an important predictor
of post-transplant outcomes [16-18]. With the introduction of
reduced-intensity conditioning (RIC) alloHCT, shown to be
associated with promising results in MDS [19-21], as well as
expanded coverage for alloHCT by Medicare under the
Coverage with Evidence Development (CED) mechanism [22],
more patients are now undergoing this curative therapy [23].
To better deﬁne the value of alloHCT, comparative analyses
are needed. Few such analyses have been performed. In a
retrospective cohort analysis, alloHCT (N ¼ 103) recipients
were 70% less likely to die (P ¼ .007) compared with patients
that only received HMAs [24]. However, this particular study
did not control for lead time bias [24], and therefore the re-
sults should be interpreted with great caution [25]. In a recent
retrospective analysis, the investigators used a multistate
statistical model to deﬁne the optimal timing of alloHCT for
MDS patients aged 60 to 70 years (N¼ 514) [26]. This analysis
demonstrated that among those with low-risk MDS (IPSS low
risk/intermediate-1), nontransplant therapies provided a
higher life expectancy, whereas among those with high-risk
MDS (IPSS intermediate-2/high risk), proceeding immedi-
ately to alloHCT was associated with higher life expectancy
than nontransplant approaches [26]. A small prospectiveFigure 1. Study schema. QOLstudy compared alloHCT with nontransplant approaches us-
ing a “donor versus no donor” comparison [27]. One hundred
sixty-three patients with intermediate/high-risk MDS were
enrolled. The distribution of donor status was as follows: 34
had no donors,115 had HLA-matched donors (identical sibling
or well-matched [HLA 10/10] unrelated donor), and 14 had
partially matched (HLA 9/10) unrelated donors. The primary
outcome (OS at 48 months) was signiﬁcantly different among
the 3 groups (P ¼ .01). The corresponding survival probabili-
ties were 17% (95% conﬁdence interval [CI], 6% to 43%), 35%
(95% CI, 26% to 49%), and 8% (95% CI, 1% to 55%). Whether the
difference between the no donor arm and the HLA-matched
donor group was signiﬁcant is unclear, however. Given the
wide CIs around these estimates, these results need to be
conﬁrmed in larger studies.
Given the lack of deﬁnitive prospective data evaluating
the relative risks and beneﬁts of alloHCT compared with
nontransplant approaches among older MDS patients and as
a response to the Centers for Medicare & Medicaid Services
(CMS) CED for National Coverage Determination of Stem Cell
Transplantation, the Blood and Marrow Transplant Clinical
Trials Network (BMT CTN) has launched the BMT CTN 1102
prospective study to address this knowledge gap [28]. In this
article we discuss the design of the BMT CTN 1102 and steps
taken to address potential sources of bias.
STUDY OVERVIEW
The fundamental question being addressed is whether
patients aged 50 to 75 years with high-risk MDS referred to
transplantation centers and for whom a suitable donor is
available have a 3-year survival advantage with RIC alloHCT
compared with nontransplant-based therapies (offered to
those without a suitable donor but transplant eligible). Other
key outcomes include leukemia-free survival, quality of life,
and cost-effectiveness.
Figure 1 depicts the overall study schema. Subjects are
enrolled at the referral visit to the transplant center. Subjects
for whom a search for an unrelated donor was initiated before
their referral to the transplant center will not be eligible for
participation in this study. However, subjects for whom sib-
ling tissue typing was initiated before their referral will be
allowed to participate. All subjects are initially assigned to the
no donor arm at the time of enrollment. Subjects with a
suitable donor will be reassigned to the donor arm when a
donor is identiﬁed. A suitable donor is deﬁned as either an
HLA-matched related donor or an 8/8 (HLA-A, -B, -C, andindicates quality of life.
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no suitable donor is identiﬁed during a 90-day interval (from
enrollment), subjects will be permanently assigned to the no
donor arm. The 90-day interval was chosen based on prior
experience from the National Marrow Donor Program that if a
donor is not found in this time frame, the subsequent likeli-
hood of ﬁnding a donor is very small.
KEY ISSUES IN STUDY DESIGN
Randomization versus Biologic Assignment
Randomized controlled trials represent the gold standard
design when one wishes to compare 2 therapies. However,
among patients who are referred for transplant evaluation
and for whom anHLA-matched donor has been identiﬁed, it is
generally viewed as not feasible to conduct a true randomized
controlled trial (ie, randomize patients with HLA-matched
donors to alloHCT versus nontransplant) [29,30]. An alterna-
tive approach is to conduct a biologic assignment trial, which
means that patients with a suitable HLA-matched donor are
assigned to the alloHCT arm, whereas patients who do not
have such a donor are assigned to the nontransplantation arm.
Biologic assignment trials have been used successfully to
evaluate the role of alloHCT across multiple hematologic
malignancies [31-36]. With this design, accrual is signiﬁcantly
enhanced, and therefore this is a more feasible design
compared with randomized controlled trials [37]. Given prior
beliefs and misconceptions regarding the value of alloHCT
among those with a donor, a biologic assignment design
provides a reasonable platform upon which the study can be
performed [37]. The BMT CTN 1102 is designed as a prospec-
tive, comparative biologic assignment study of RIC alloHCT
from related and unrelated donors versus hypomethylating
therapy or best supportive care among patients with
intermediate-2/high-risk de novo MDS.
Although selection bias can arise in biologic assignment,
it is the most feasible design for this trial. The study was
carefully designed and adjusted analysis planned to mini-
mize potential bias as discussed below.
Enrolling at Referral to Transplant Program versus Other
Time Points (eg, at Diagnosis or at Complete Remission)
Because most newly diagnosed MDS patients are treated
by community oncologists, it is difﬁcult to recruit patients at
diagnosis before they have received therapy. Unlike acute
leukemias where a complete remission is the objective of
induction chemotherapy (and therefore an ideal time to
enroll patients onto a study that evaluates consolidative
strategies), induction chemotherapy is rarely used at the
time of initial MDS diagnosis, and a complete remission oc-
curs in few MDS patients on HMAs, rendering enrollment at
complete remission neither a clinically meaningful nor
feasible time point [12,14]. The BMT CTN 1102 addresses the
fundamental question of whether RIC alloHCT offers a sur-
vival advantage compared with nontransplant therapies
among older MDS patients who are believed to be trans-
plantation candidates. Therefore, enrolling patients at the
time of referral would seem to be a reasonable approach.
Enrollment Bias and Prognostic Factor Imbalances
Given the lack of randomization, biologic assignment
trials are inherently vulnerable to enrollment bias and
prognostic factor imbalances. A detailed discussion of
enrollment bias in the setting of biologic assignment trials
has been published elsewhere [37]. To reduce bias and
assemble the proper control group for the “donor arm,” it iscritical to enroll patients without knowledge of whether a
donor is available or not. Therefore, patients whose tissue
typing for unrelated donors was initiated before referral will
not be eligible. Patients whose tissue typing for a sibling
donor was initiated before referral will still be eligible. The
latter should not risk enrollment bias, because patients in
whom the tissue typing rules out available sibling donors
will still be considered for an HLA-matched unrelated donor
transplant. Additionally, a multivariate analysis is planned
that will adjust for any serious imbalances in baseline
characteristics.
Potential Bias Introduced During Donor Search
Excessive early deaths (“early” indicates no suitable
donor is identiﬁed and the 90-day window is not yet
reached) could potentially bias the study in favor of the RIC
alloHCT arm, because subjects who die before a donor is
identiﬁed will be analyzed in the no donor arm. Conversely,
subjects with an already identiﬁed sibling donor (which
means immediate assignment to the donor arm) referred to
the transplant center who experience early death (“early”
indicates death occurring less than 90 days from enrollment
and before RIC alloHCT is actually performed) are analyzed
in the donor group, which could bias the study in favor of
the nontransplant arm. The protocol team will monitor the
rates of early death carefully and will report them to the
Data Safety Monitoring Board. The protocol team expects
that these early deaths rates will be very small given that
these patients were believed to be eligible to undergo
alloHCT within the preceding 2 to 3 months.
Eligibility Criteria
Patients with de novo MDS are eligible irrespective of
how long they had MDS [38]. Patients must have (or previ-
ously had) an intermediate-2 or high-risk IPSS stage [5]. Our
intent is to include patients in whom a RIC alloHCT is
preferred based on physician’s assessment. Patients younger
than 50 years of age typically undergo high-intensity con-
ditioning alloHCT [23]. Therefore, subjects aged 50 to
75 years will be eligible to participate.
For subjects to be assigned to the donor arm, a suitable
donor must be identiﬁed, which as previously stated is
deﬁned as either HLA-matched related donor or 8/8 HLA
well-matched unrelated donor. Two analyses informed the
decision to restrict donor types to only these 2. First, we
recently reported outcomes of 701 MDS patients (median
age 53 years [range, 22 to 78]) after HLA-identical sibling
versus 8/8 (HLA-A, -B, -C, and DRB1) matched unrelated
donor versus 7/8 HLA partially matched unrelated donor
alloHCT [39]. In the multivariate analysis, HLA-identical
sibling HCT recipients had similar survival compared with
8/8 matched unrelated donor HCT recipients, and both HLA-
identical sibling and 8/8 matched unrelated donor groups
had superior survival compared with 7/8 HLA partially
matched unrelated HCT recipients (Table 1) [39]. Second,
using data from the CIBMTR, we conducted an exploratory
analysis to determine the impact of different donor sources
on post-alloHCT outcomes in patients with MDS (unpub-
lished data, June, 2012). We selected patients who were at
least 21 years of age who received an alloHCT for MDS be-
tween 2000 and 2010 in the United States. Donor sources
were HLA-identical sibling (n ¼ 1458), well-matched unre-
lated donors (n ¼ 1091), partially matched unrelated donors
(n ¼ 273), cord blood (n ¼ 153), and haploidentical donors
(n ¼ 95). Median age at HCT was 54 (range, 21 to 81), and
Table 1
Multivariate Analysis of a Cohort of Adult MDS Patients Who Underwent HLA-Identical Sibling HCT or 8/8 or 7/8 Matched Unrelated Donor (MUD) HCT From
2002 to 2006
Transplant-Related
Mortality
Relapse Treatment Failure (Death
or Relapse)
Mortality
RR (95% CI) P RR (95% CI) P RR (95% CI) P RR (95% CI) P
8/8 MUD vs. MRD 1.43 (1.06-1.95) .02 .85 (.60-1.18) .33 1.13 (.91-1.42) .26 1.24 (.98-1.56) .06
7/8 MUD vs. MRD 1.80 (1.23-2.63) .002 1.02 (.66-1.60) .91 1.47 (1.10-1.96) .008 1.62 (1.21-2.17) .001
7/8 MUD vs. 8/8 MUD 1.25 (.91-1.72) .16 1.21 (.81-1.81) .35 1.29 (1.00-1.66) .04 1.30 (1.01-1.68) .03
MRD indicates matched related donor; RR, relative risk. Adapted from Saber et al. [39].
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variate analysis, survival was signiﬁcantly lower for partially
matched unrelated donors, umbilical cord graft, and hap-
loidentical donor alloHCT compared with HLA-identical sib-
ling and well-matched unrelated donor alloHCT (P < .001).
Survival was not signiﬁcantly different (P ¼ .56) among the
3 alternative donor groups (Supplemental Table 1).
Together, these analyses suggest that transplantation
from alternative donors is associated with signiﬁcantly
poorer outcomes than transplantation from HLA-identical
sibling and well-matched unrelated donors. Therefore, only
HLA-identical siblings or 8/8 HLA well-matched unrelated
donors are considered suitable donor types in this study.
Physicians and patients participating in this study should
have no intention to pursue alternative donor HCT if a suit-
able donor is not available. In addition, if a suitable donor is
available, the intention should be to proceed to RIC alloHCT
as soon as possible.
The outcomes of therapy-related MDS with nontrans-
plant therapies are quite dismal. A recent analysis by Bally
et al. [40] suggested a 2-year survival of 14% with DNA HMAs.
Given the grim prognosis with HMAs, these patients may
beneﬁt from an alloHCT from an alternative donor even if a
suitable donor is not available, and therefore patients with
therapy-related MDS are excluded from this study.RIC AlloHCT Regimens
The actual choice of regimen is left to the discretion of the
treating physician. However, regimens must be declared by
the center as a preferred regimen to ensure alloHCT is per-
formed according to the institutional standard. The rationale
for not specifying a particular RIC regimen is further sup-
ported by analysis of data reported to the CIBMTR (un-
published data, June, 2012). In the univariate analysis of
outcomes of MDS patients aged 50 to 75 years who under-
went RIC alloHCT between 2005 and 2011, and controlling
for donor type, we found no signiﬁcant difference in survival
between the different RIC regimens (Supplemental Table 2).Nontransplant Regimens
The protocol does not mandate particular nontransplant
therapy. However, we expect most patients will be treated
with HMAs. We acknowledge that nontransplant treatments
used for patients in the control arm may vary. However, no
nontransplant therapies produce cures in patients with
high-risk MDS, and most nontransplant patients will receive
the few US Food and Drug Administrationeapproved and
available therapies when appropriate. The poor outcomes
associated with these therapies are demonstrated in
Supplemental Table 3. Data on the type of nontransplant
therapies will be captured (ie, whether HMAs were received
or not, number of cycles, duration of therapy).Feasibility
Based on historical CIBMTR data and assuming an accrual
rate of 40%, we expect annual enrollment of 84 patients to
the RIC alloHCT arm. The length of time required to accrue
the targeted sample size for this study depends on the
proportion of enrolled patients with a suitable donor.
Supplemental Table 4 provides estimated annual accruals for
various proportions of donor availability. Based on these
assumptions, it is estimated that 2.5 to 3.5 years of accrual
will be necessary to enroll the targeted sample size.
Data Collection for Subjects Assigned to the No Donor
Arm
Subjects assigned to the no donor armwill continue to be
followed by their primary hematologists. The HCT centers
that enrolled and registered the patients will be responsible
for periodic contact (every 3 months for Years 1 and 2, every
6 months in Year 3, 1 month) with the primary hematolo-
gists. Documentation of transformation to AML will be
requested, as well as treatment history. Vital status (death or
alive) and date of the last follow-up or deathwill be recorded.
Data Collection for Subjects Assigned to the Donor Arm
The schedule of follow-up for subjects assigned to the
donor arm but had not yet undergone alloHCT will follow the
same schedule outlined above for the no donor arm. Once
transplanted, the follow-up will be through submission of
CIBMTR pre- and post-transplant comprehensive Report
Forms. In the event that patients with donors do not undergo
transplantation, the follow-up will remain the responsibility
of the transplant center, with the same schedule outlined
above for the no donor arm.
KEY ISSUES IN STUDY ANALYSIS
Intention-to-Treat versus As-Treated Analysis
To minimize bias that may occur after assignment,
intention-to-treat analysis is planned as the primary anal-
ysis. Table 2 gives examples that illustrate how the intention-
to-treat principle will be maintained when events occur
during the 90-day interval and beyond. Additional sensitivity
analyses excluding patients who died or dropped out before
90 days from enrollment as well as a secondary analysis
using as-treated principles will also be conducted.
Statistical Power
Secondary analyses of published data from the CIBMTR
for high-risk MDS patients older than age 50 suggest 3-year
OS estimates between 35% and 40% [39]. Based on data from
a compassionate use program of DNA HMAs, the 3-year OS
probabilities for the nontransplant arm are estimated to
range between 20% and 25% [41]. Based on these data, we
expect to observe an absolute difference of 15% in 3-year OS
probabilities in favor of patients assigned to the RIC alloHCT.
Figure 2. US alloHCTs for MDS patients older than 65 years from 2005 to 2013.
BMT indicates bone marrow transplant.
Table 2
Examples of Treatment Arm Assignment and Subsequent Analysis Based on
Suitable Donor Identiﬁcation
Scenario Arm
A transplant donor is identiﬁed 30 days from consent.
The subject undergoes transplantation 70 days
from consent.
RIC alloHCT
A transplant donor is identiﬁed 30 days from consent.
The subject receives 4 cycles of hypomethylating
therapy and undergoes transplantation 200 days
from consent.
RIC alloHCT
A transplant donor is identiﬁed 30 days from consent.
The subject receives 4 cycles of hypomethylating
therapy and dies related to an infection before
transplantation.
RIC alloHCT
The patient has an identiﬁed sibling donor on the date
of consent. The patient eventually declines
transplantation.
RIC alloHCT
A donor search is begun after enrollment, and the
subject begins hypomethylating therapy. The
subject dies 80 days after consent without a donor
being identiﬁed.
Nontransplant
arm
A donor search is begun after enrollment, and the
subject begins hypomethylating therapy. No donor
is identiﬁed after a 90-day search. The subject
continues on hypomethylating therapy.
Nontransplant
arm
A donor search is begun after enrollment, and the
subject begins hypomethylating therapy. No donor
is identiﬁed after a 90-day search. The subject
progresses and undergoes alternative donor
transplantation 150 days from consent.
Nontransplant
arm
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power (at least 80% power) for various combinations of
baseline survival probability and donor availability. It is ex-
pected that 60% to 70% of patients will have a donor. The
required sample size increases with higher percentage of
donor availability.
Planned Subgroup Analyses
The value of HMA therapy pre-HCTdand, more specif-
ically, the “optimal” timing to refer a patient on HMA therapy
for transplantation evaluationdremains unknown. Retro-
spective analyses have examined the impact of pre-HCTHMA
therapy on post-HCT outcomes. The largest study included
163 individuals who underwent HCT after azacitidine and
after leukemia-type induction chemotherapy. There were no
differences in post-HCT outcomes [42]. A smaller study from
Seattle demonstrated a slight advantage of pre-HCT therapy
with azacitidine over induction chemotherapy, potentially
because of reduced toxicity [43]. Both studies, however,
lacked the size of the original patient population initially
considered for transplantationdthe actual denominatord
without which it is impossible to determine the role of one
pre-HCT approach versus another. Other retrospective ana-
lyses compared pre-HCT HMA therapy with no treatment
and showed no beneﬁt to HMA therapy. These studies were
affected by similar selection biases as mentioned above
[44,45]. Predeﬁned subgroup analyses to determine the
impact of pre-HCT HMA therapy (including response to HMA
therapy) on the study outcomes will be performed to address
this important question. Additional predeﬁned subgroup
analyses will examine the impact of the following factors on
treatment effect: patient age (<65 years versus 65 years),
disease duration, and IPSS and IPSS-R.
DISCUSSION
Understanding the relative risks and beneﬁts of alloHCT
can move the ﬁeld signiﬁcantly forward. We believe thecurrent study design affords the best practical approach to
achieving this goal in a relatively unbiased fashion. Despite
the potential limitations discussed above, the strength of the
current design is that it is likely to result in successful accrual
by (1) having eligibility criteria that will capture a large
segment of the patients referred for transplantation, (2)
allowing ﬂexibility in both transplant and nontransplant
therapies administered, (3) minimizing the data collection
burden, and (4) providing the optimal comparator groups
given the constraints discussed above. It also allows for
quality-of-life and cost-effectiveness studies, which are be-
ing planned in a “real world” population of patients.
Recently, a Data Safety Monitoring Board recommended that
the National Heart, Lung, and Blood Institute prematurely
terminate BMT CTN 0901 (Cinicaltrials.gov identiﬁer:
NCT01339910 [46]) because preliminary data suggested that
high-intensity regimens were associated with superior out-
comes compared with RIC regimens permitted in the study
among patients with AML and MDS who were eligible to get
either regimen intensities. Because the data were not sufﬁ-
ciently mature to perform subgroup analysis based on dis-
ease type, it is not known currently whether these
preliminary ﬁndings are consistent among AML versus MDS
patients. These analyses will be performed in the future. We
acknowledge that these preliminary results might lead some
physicians to prefer higher intensity regimens in some pa-
tients otherwise eligible for BMT CTN 1102. However, we
believe the proportion will be relatively low, because the
eligibility criteria for BMT CTN 1102 from the start were only
patients believed to be candidates for RIC alloHCT and not
high-intensity regimens (because of comorbidities or age).
Patients who are candidates for higher intensity regimens
are not currently eligible for enrollment onto BMT CTN 1102.
The results of the BMT CTN 1102 have the potential to
change practice. If this study demonstrates a signiﬁcant
survival advantage with alloHCT, we expect the number of
patients transplanted would increase signiﬁcantly, setting
the stage for more reﬁned studies. In fact, emerging data
from an ongoing single-arm prospective study conducted at
the CIBMTR to evaluate safety of alloHCT for older MDS pa-
tients [18], also made possible by the expanded coverage for
the alloHCT by Medicare under the CED mechanism [22],
clearly show that under this coverage mechanism the num-
ber of HCTs have risen dramatically (Figure 2). These data
strongly support that barriers to access to alloHCT care is
affecting the decision to refer patients for transplant evalu-
ation. The BMT CTN 1102 has recently gained approval by the
CMS, and therefore costs of alloHCT for Medicare
W. Saber et al. / Biol Blood Marrow Transplant 20 (2014) 1566e1572 1571beneﬁciaries enrolled onto this study will be covered. If the
study demonstrates survival advantage with alloHCT, this
will have signiﬁcant implications with respect to coverage of
costs of alloHCT for MDS by the CMS for all Medicare bene-
ﬁciaries in the future. Alternatively, if the study fails to show
an advantage to allogeneic HCT, it will make us dramatically
rethink howwe approach the problem of MDS in this patient
population. Finally, if the study fails to accrue adequate
numbers of patients for completion in a timelymanner, there
is the deﬁnite risk that Medicare will choose to no longer
continue coverage and we will never know the answer.ACKNOWLEDGMENTS
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